Mobocertinib (TAK788)
$200.00
CAS No.: 1847461-43-1
Catalog No.: 193733
Purity: 95%
MF: C32H39N7O4
MW: 585.709
Storage: 2-8 degree Celsius
SMILES: C(C=C)(=O)NC=1C(=CC(=C(C1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C
Catalog No.: 193733
Purity: 95%
MF: C32H39N7O4
MW: 585.709
Storage: 2-8 degree Celsius
SMILES: C(C=C)(=O)NC=1C(=CC(=C(C1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C
Mobocertinib (TAK788); isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; CAS No.: 1847461-43-1;1Mobocertinib (TAK788). PROPERTIES: Mobocertinib is a white to pale yellow powder with a molecular formula of C30H30N6O4 and a molecular weight of 554.60 g/mol. It shows moderate lipophilicity with a logP value of approximately 3.2. Storage recommendations include keeping it at -20 C in a dry environment protected from light. Standard laboratory safety precautions apply, including avoiding skin contact and using proper ventilation when handling due to its pharmaceutical nature. APPLICATIONS: Mobocertinib is a selective and irreversible inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations. In clinical oncology, it's used for treating non-small cell lung cancer (NSCLC) patients with these specific mutations who have progressed on platinum-based chemotherapy (source: New England Journal of Medicine). Phase I/II trials demonstrated meaningful antitumor activity with an objective response rate of approximately 43% in previously treated patients. Mobocertinib's application extends to companion diagnostic development, helping identify patients most likely to benefit from targeted therapy (source: Journal of Thoracic Oncology).
Reviews
Write Your Own Review